
Poorly controlled blood glucose in patients with diabetes hospitalized for COVID-19 significantly reduces odds of survival.

Poorly controlled blood glucose in patients with diabetes hospitalized for COVID-19 significantly reduces odds of survival.

The SGLT-2 inhibitor is the first in its class to be approved for the treatment of adults with NYHA class II, III, or IV heart failure with reduced (≤40%) ejection fraction.

For your diabetes patients at home or soon to be at home, use these tips from the ADA and AACE on creating an emergency plan.

These 3 case studies illustrate the challenges of intensifying treatment in complex T2D patients--and also the options available to individualize that next step.

Global leaders in obesity research plus hundreds of medical, scientific, & academic associations and institutions have taken this pledge to end the stigma.

Obesity stigma is pervasive & resilient. A landmark statement demands we eliminate the gap between the social narrative and scientific evidence.

More than 50% of patients with obesity say weight loss is a priority for them. What percentage of their physicians feel the same? #ObesityCareWeek

Irregular sleep patterns in women may impact quality of diet and calories consumed, increasing risk for cardiometabolic disease, concludes a new study.

Liraglutide added to intensive behavior therapy in primary care practice significantly improved weight loss vs behavior therapy alone, a new study found.

Based on results from REWIND, dulaglutide is the first GLP-1 receptor agonist to be approved for both primary and secondary CV prevention in type 2 diabetes.

Weight Watchers (WW), Jenny Craig, and the Nutrarian Diet top the list of 10 best brand-name diet plans. Get highlights here, then find out what your patients are reading.

Which 5 diets are best for your diabetes patients out of the 35 ranked most popular by US News & World Report health experts?

Over 70% of US adults with diabetes have hypertension, 15.6% of these patients have an A1c value >9%, and more fast facts on diabetes risk factors and patient characteristics.

The new 3-in-1 oral therapy may help reduce treatment burden for T2D patients who most often require multiple agents.

Of 35 of the most popular diets ranked by health experts, we highlight the top 10. The "Best Diets" issue reached your patients this month. See what they're reading.

A US diabetes diagnosis is made every 21 seconds; 40% of millennials with T2DM can't pay for treatment. And there is more PCPs will want to know.

When compared to standard diet and exercise, a new review found metformin more effective in type 2 diabetes prevention.


Treatment with liraglutide for 26 weeks had no impact on bone resorption in patients with T2D, say authors of a new study.

Dapagliflozin received FDA priority review for reducing risk of CV death in adults with heart failure with reduced ejection fraction.

Type 1 diabetes patients who used the new system increased by 2.6 hours/day the amount of time spent in target blood glucose level range.

The SGLT2 inhibitor, on October 21, 2019 was granted a label expansion from FDA for the prevention of hospitalization for heart failure in patients with T2D.

For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.

The SGLT-2 inhibitor canagliflozin was FDA-approved on September 30, 2019, to slow progression of diabetic kidney disease and reduce risk of heart failure hospitalization.

Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.